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Cholesterol uptake and efflux are key metabolic processes associated with macrophage physiology and ath-
erosclerosis. Peroxisome proliferator-activated receptor gamma (PPAR) and liver X receptor alpha (LXR)
have been linked to the regulation of these processes. It remains to be identified how activation of these re-
ceptors is connected and regulated by endogenous lipid molecules. We identified CYP27, a p450 enzyme, as a
link between retinoid, PPAR, and LXR signaling. We show that the human CYP27 gene is under coupled
regulation by retinoids and ligands of PPARs via a PPAR-retinoic acid receptor response element in its
promoter. Induction of the enzyme’s expression results in an increased level of 27-hydroxycholesterol and
upregulation of LXR-mediated processes. Upregulated CYP27 activity also leads to LXR-independent elimination
of CYP27 metabolites as an alternative means of cholesterol efflux. Moreover, human macrophage-rich athero-
sclerotic lesions have an increased level of retinoid-, PPAR-, and LXR-regulated gene expression and also
enhanced CYP27 levels. Our findings suggest that nuclear receptor-regulated CYP27 expression is likely to be a
key integrator of retinoic acid receptor-PPAR-LXR signaling, relying on natural ligands and contributing to lipid
metabolism in macrophages.
Handling of lipids by macrophages is an important meta-
bolic process in the context of hypercholesterolemia and the
development of atherosclerotic lesions (20, 32, 44). For this
reason it is critical to understand the regulatory processes
associated with cholesterol and fatty acid uptake and release
(efflux) in this cell type. A regulatory network has been asso-
ciated with macrophage lipid metabolism in recent years. First,
it has been shown that peroxisome proliferator-activated re-
ceptor gamma (PPAR), a member of the nuclear receptor
superfamily, can be linked to macrophage maturation and up-
take of modified (oxidized) low-density lipoprotein (LDL) (35,
45). Later, the oxysterol receptor liver X receptor (LXR) was
linked to macrophage lipid metabolism by showing that LXR
is a direct transcriptional target of PPAR and could induce
lipid transporters such as ABCA1 (9, 40) and ABCG1 (26). A
coordinated lipid transport is likely to be regulated by these
receptors. Linking of the two receptor systems (PPAR and
LXR) provides an attractive but not well understood pathway
to explain lipid and cholesterol uptake and efflux from macro-
phages. The issue of how the activation of the two receptors
may be coupled has not been addressed yet. It was assumed
that the lipid contents of lipoproteins may act as activators or
ligands for both PPAR (35) and LXR (30). The fact that LXR
signaling is activated in macrophages exposed to acetylated
LDL (30), which does not contain oxidized cholesterol, sug-
gests that there must be other ways to activate or produce
ligand for this receptor. Furthermore, LXR-RXR hetero-
dimers were originally identified as mediators of an alternative
retinoid signaling pathway (47, 48) showing that the LXR-
RXR heterodimer is highly permissive and can be activated
from either the RXR side by retinoids or the LXR side by
oxysterols (40). These observations and the fact that RXR
agonists have atheroprotective effects in ApoE/ animals (11)
suggest that retinoids may also participate in the regulation of
lipid homeostasis. A number of oxysterols were identified as
potential endogenous ligands for LXR (24, 25, 31, 36). One of
these compounds, 27-hydroxycholesterol, is produced by a
p450 enzyme, CYP27. CYP27 is a mitochondrial enzyme rep-
resenting an alternative bile acid synthesis pathway (1, 8, 37,
42, 43) and was reported to be expressed, besides in the liver,
in the lung and also in macrophages (2, 5). It has been also
associated with atherosclerotic lesions (13, 23). A mutation in
this enzyme leads to the human disease cerebrotendinous xan-
thomatosis (CTX), a rare sterol storage disease characterized
by xanthomas in tendons and also in the central nervous system
leading to ataxia, spinal cord paresis, neurological dysfunc-
tions, normolipidemic xanthomatosis, and accelerated athero-
sclerosis (6, 7, 33). The enzyme’s product, 27-hydroxycholes-
terol, has been shown to activate LXR (17, 25). By carrying out
global gene expression profiling in a search for common ele-
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ments of monocyte-macrophage transition and PPAR-RXR-
mediated transcriptional events, we identified CYP27 as an
element of monocyte-macrophage transition (22) and also as
part of the realm of PPAR-RXR-regulated genes in myeloid
cells. Here we show that human CYP27 is transcriptionally
regulated by both retinoids and PPAR ligands, based on inter-
actions on a response element in the promoter region of the
gene. Furthermore, retinoids induce LXR-regulated lipid trans-
porters mediating cholesterol efflux. Finally, all elements of
this pathway can be found in human macrophage-rich athero-
sclerotic lesions.
MATERIALS AND METHODS
Materials. Cells were treated with the following ligands: AM580 (Biomol);
LG268 (a gift from R. Heyman) (Ligand Pharmaceuticals); Wy14643, Rosigli-
tazone, and T0901317 (Alexis Biochemicals); GW501516 and GW9662 (gifts
from T. M. Willson) (GlaxoSmithKline); 27-hydroxycholesterol, 25-hydroxycho-
lesterol, 24S,25-epoxycholesterol, and 22R-hydroxycholesterol (Steraloids Inc.);
9-hydroxyoctadecadienoic acid (Cayman Chemicals); LDL and oxidized LDL
(Intracel); and AGN193109 (a gift from Roshantha A. S. Chandraratna) (Aller-
gan Inc.). All other reagents were obtained from Sigma or as indicated.
Plasmids. Mammalian expression vectors expressing human retinoic acid re-
ceptor alpha (RAR), human retinoid X receptor alpha (RXR), mouse PPAR
(mPPAR), -galactosidase, and thymidine kinase (TK)-Luc were described
previously (10). The hCYP27-853-pCAT, hCYP27-649-pCAT, and hCYP27-217-
pCAT plasmids were constructed earlier (18). pcDNA3.1-hCYP27 was a gift
from E. G. Lund (Merck Research Laboratories, Rahway, N.J.).
Cell culture. MonoMac-6 cells were kind gift of E. Duda (Biological Research
Center, Szeged, Hungary). The cells were grown in RPMI 1640 (Sigma) supple-
mented with 10% fetal bovine serum (FBS) (Invitrogen), 10% charcoal-stripped
serum (Invitrogen), or 10% lipoprotein-deficient serum (Intracel), along with
2 mM glutamine, penicillin, and streptomycin (Sigma), or without serum in the
presence of insulin-transferrin-sodium selenite medium supplement (Sigma), or
in AIMV (Invitrogen). Primary human fibroblasts were isolated from healthy
adults and patients with CTX as described earlier (19) and were cultured in
DMEM (Sigma) supplemented with 10% FBS, 2 mM glutamine, penicillin, and
streptomycin.
Microarray analysis. Total RNA was isolated by using Trizol reagent (Invitro-
gen) and further purified by using the RNeasy kit (Qiagen). cRNA was generated
from 5 g of total RNA by using the SuperScript Choice kit (Invitrogen) and the
high-yield RNA transcription labeling kit (Enzo Diagnostics). Fragmented
cRNA was hybridized to Affymetrix (Santa Clara, Calif.) arrays (HU95A) ac-
cording to standard Affymetrix protocols. Preliminary data analysis was per-
formed by the Microarray Core Facility of the Howard Hughes Medical Institute
at Stanford University. Further analysis was performed with GeneSpring 6.0
(Silicon Genetics, Redwood City, Calif.). These analyses provided a signal for
each specific transcript that was subsequently normalized by comparison to the
median signal (arbitrary value of 1.0) obtained from the whole array.
Isolation and culture of human primary monocytes. Human monocytes were
isolated from healthy volunteer buffy coat obtained from the regional blood
bank. Monocyte separation was carried out according to the manufacturer’s in-
structions with CD14 MicroBeads (Miltenyi Biotec). Monocytes were differen-
tiated for 2 to 4 days. Primary human cells were cultured in RPMI 1640 sup-
plemented with 10% FBS, 2 mM glutamine, penicillin, and streptomycin or as
indicated.
RNA extraction and real-time quantitative PCR. Total RNA was isolated from
cells by using Trizol reagent (Invitrogen) according to the instructions of the
manufacturer. Atherosclerotic lesions were dissected off from underlying tissues
and homogenized. Control samples were obtained from the neighboring non-
atherosclerotic part of the vessel wall. For the human samples, lesion areas
(abnormal, fatty, nonulcering lesions of the femoral artery and the common and
internal carotid arteries) were dissected off. After homogenization, total RNA
was extracted with Trizol reagent. Transcript quantitation was performed by
quantitative real-time reverse transcriptase PCR (RT-PCR) with TaqMan
probes. Transcript levels were normalized to the level of cyclophilin D and 36B4.
The sequences of primers and TaqMan probes used in transcript quantitation are
available at http://biochem.dote.hu/nagylab.
Northern blot analysis. Total RNA (10 to 15 g) was separated by formalde-
hyde–1% agarose gel electrophoresis and transferred to a nylon membrane that
was hybridized with radioactive [-32P]dATP-labeled DNA probes by using a
random hexamer DNA labeling kit (Fermentas) and QuickHyb hybridization
solution (Stratagene). Transcript levels were determined after overnight expo-
sure to Kodak X-OMAT films and were normalized for 36B4 expression levels.
Western blot analysis. Cells were treated for 2 days as indicated, washed in
phosphate-buffered saline, and then lysed in buffer A (Tris-HCl [pH 7.5], 1 mM
EDTA, 15 mM -mercaptoethanol, 0.1% Triton X-100, 0.5 mM phenylmethyl-
sulfonyl fluoride. Twenty-five micrograms of total protein was separated by so-
dium dodecyl sulfate (SDS)–10% polyacrylamide gel electrophoresis and trans-
ferred to polyvinylidene difluoride membrane (Bio-Rad Laboratories). After
blocking with 5% dry milk, the membrane was probed with anti-CYP27 antibody,
a kind gift from D. W. Russell (University of Texas Southwestern Medical Center,
Dallas) and subsequently with peroxidase-conjugated secondary antibody. An en-
hanced chemiluminescence detection kit (Pierce) was used for signal detection.
Chromatin immunoprecipitation. Chromatin immunoprecipitation was car-
ried out as described previously (27) with modifications. Briefly, cells were fixed
with 1% formaldehyde for 10 min at room temperature. Fixation was stopped by
adding chilled glycine to a final concentration of 150 mM. The cells were scraped
and washed twice with ice-cold phosphate-buffered saline containing proteinase
inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 g of aprotinin per l, and 1
g of pepstatin A per l). Nuclei were prepared by incubation for 10 min on ice
in a buffer containing 5 mM PIPES [piperazine-N,N-bis(2-ethanesulfonic acid)]
(pH 8), 85 mM KCl, 0.5% NP-40, and proteinase inhibitors. After centrifugation
at 3,000  g for 10 min at 4°C, nuclei were resuspended in sonication buffer (1%
SDS, 0.1 M NaHCO3, and proteinase inhibitors), lysed on ice for 10 min, and
sonicated on ice to an average fragment size of 300 bp. Cell debris was pelleted
twice by centrifugation at 10,000  g for 30 min at 4°C in a bench top centrifuge.
Soluble chromatin was aliquoted, frozen in liquid nitrogen, and stored at 70°C.
For immunoprecipitation, chromatin was diluted 10-fold in immunoprecipitation
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris [pH 8.1],
16.7 mM NaCl, and proteinase inhibitors). One milliliter of diluted chromatin
was precleared twice with 40 l of blocked protein A/G-Sepharose beads. Im-
munoprecipitation was carried out with specific antibodies purchased from
Upstate Biotechnology (anti-acetyl H4 2) and Santa Cruz (anti-PPAR and
anti-RXR). Anti-RAR was a kind gift of L. Tora (CNRS/INSERM/ULP,
Strasburg, France). Immunoprecipitated nucleosomes were eluted twice from beads
with elution buffer (1% SDS, 0.1 M NaHCO3), and eluates were combined. Cross-
links were reversed by incubation for 6 h at 65°C after addition of 20 l of 5 M NaCl.
The eluate was combined with 10 l of 0.5 M EDTA, 20 l 1 M Tris (pH 6.5), and
2 g of proteinase K and incubated for 1 h at 45°C. DNA was recovered after
phenol-chloroform extraction and ethanol precipitation with 20 g of glycogen as
a carrier. The DNA was resuspended in 50 l of yeast tRNA (50 ng/l) (Invitro-
gen). Two microliters of this solution was used for real-time Q-PCR in a 25-l
reaction mixture. All measurements were done in triplicate. All chromatin results
were verified from independent chromatin preparations.
Transient transfections and reporter gene assays. Human CYP27-chlor-
amphenicol acetyltransferase (CAT) promoter plasmids were constructed as
described earlier (18). The following deletion constructs were used and cotrans-
fected with the indicated full-length receptors: hCYP27-853-pCAT, hCYP27-
649-pCAT, hCYP27-217-pCAT (numbers indicate positions relative to the trans-
lational start site,1). The response elements were cloned into TK-Luc to obtain
Enhancer trap vectors that were transfected along with the indicated receptors.
All transfection experiments were performed with CV1 cells (green monkey
kidney fibroblasts) as described earlier (45).
Electrophoretic mobility shift assays. Electrophoretic mobility shift assays
were performed as described earlier (4). Full-length hRAR, hRXR, and
mPPAR receptors were produced by using the T7 Quick TNT in vitro tran-
scription-translation kit (Promega). For supershift experiments, the receptors
were preincubated with the indicated antibody prior to binding reaction: anti-
RAR (Santa Cruz), anti-RXR (a kind gift from L. Tora, CNRS/INSERM/ULP,
Strasburg, France), or anti-PPAR (Biomol). The oligonucleotides that were
used are available at http://biochem.dote.hu/nagylab.
Determination of 27-hydroxycholesterol and 3-hydroxy-5-cholestenoic acid.
Levels of 27-oxygenated sterols were determined as described previously (2).
Briefly, 106 cells were treated as indicated in the figures, and 27-hydroxycholes-
terol and 3-hydroxy-5-cholestenoic acid contents were measured by quantitative
mass spectrometry with use of deuterium-labeled 27-hydroxycholesterol and
3-hydroxy-5-norcholestenoic acid, respectively, as internal standards.
Determination of retinoid levels. Retinoid levels were determined by high-
performance liquid chromatography (HPLC) as described previously (41).
Statistical analysis. All data are presented as means 	 standard deviations
(SD). In real-time quantitative PCR and transient-transfection experiments, the
mean and SD were calculated for both the normalized and the normalizer values.
To incorporate the random errors of the measurements, we used the propagation
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of errors to determine the SD of the normalized values. For all experiments we
made at least four biological replicates, and on the fold changes we performed an
F test followed by an unpaired (two-tailed) t test; results were considered sig-
nificant with a P value of 
0.01.
RESULTS
Human CYP27 is acutely regulated by retinoids and PPAR
agonists. In order to identify the common elements of the tran-
scriptional changes during the monocyte-macrophage tran-
sition and that of PPAR-RXR heterodimer activation, we have
carried out DNA microarray analysis on monocytic leukemia
cells (MonoMac-6) treated with PPAR (Rosiglitazone) and
the RXR-selective retinoid LG268 and also on primary human
monocytes induced to differentiate to macrophages as de-
scribed in Materials and Methods. As part of these global gene
expression profiling efforts, we found that transcript levels of
the p450 enzyme CYP27 increased in monocyte-derived mac-
rophages and also in PPAR and RXR ligand-treated myeloid
cells, along with several other genes associated with lipid me-
tabolism (data not shown), suggesting that these genes may be
under PPAR and/or retinoid regulation. In order to provide
a baseline for further studies, we determined the transcript
levels of various nuclear receptors (PPARs, retinoid receptors,
and LXR) during the monocyte-macrophage transition. Com-
paring the relative abundances of nuclear receptor transcript
levels by quantitative PCR, we found increased PPAR and
LXR levels (Fig. 1A and B). Strikingly, this was paralleled by
an increase in transcript levels of CYP27 (Fig. 1C), the enzyme
with the potential to produce a soluble cholesterol metabolite
and a ligand for LXR.
It was intriguing to speculate that there was a link between
the well-established PPAR-LXR signaling and induction of
CYP27 in macrophages. Therefore, we decided to determine
whether ligand activation of nuclear receptor pathways could
activate CYP27 gene transcription. Using monocyte-derived
macrophages and the monocytic leukemia cell line (MonoMac-
FIG. 1. Regulated expression of CYP27 by retinoids and PPAR activators. Total RNAs isolated from primary human monocytes (Mo) and
macrophages (M) or MonoMac-6 cells after 2 days in culture were used for real-time quantitative RT-PCR analysis as described in Materials
and Methods. Absolute molecule numbers of PPAR (A), LXR (B), and CYP27 (C) were determined and normalized to cyclophilin levels. Every
transcript was measured in triplicates. Primary human monocytes were treated with Rosiglitazone (D, E, and F) or MonoMac-6 cells (G, H, and
I) and cultured in the presence of the indicated ligands or vehicle (ATRA. 1 M; 9-cis-RA, 1 M; AM580 [RAR agonist], 100 nM; LG268 [RXR
agonist], 100 nM; WY14643 [PPAR agonist], 10 M; Rosiglitazone [PPAR agonist], 1 M; GW501516 [PPAR agonist], 1 M; T0901317
[LXR agonist], 1 M). (D, E, F, G, and I) After 2 days, total RNA was isolated and real-time quantitative RT-PCR analysis was performed. The
means of at least three independent measurements 	 SD are presented. (H) Northern analysis was performed on total RNA isolated from
MonoMac-6 cells as described in Materials and Methods. Membranes were probed with labeled CYP27 and 36B4 cDNA probe. *, P 
 0.01;
**, P 
 0.05 (compared to the respective control value).
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6), we tested the effect of RAR-, RXR-, PPAR-, and LXR-
specific ligands on the expression of CYP27. The results of
Northern blot and quantitative RT-PCR analyses are pre-
sented in Fig. 1D to I. We found that retinoids and activators
of PPAR could induce the CYP27 transcript to high levels in
human macrophages (Fig. 1D and E). To further substantiate
the Rosiglitazone induction, a dose-response experiment was
carried out (Fig. 1E) and showed that CYP27 is induced by
Rosiglitazone in a dose-dependent manner similarly to the
bone fide target gene for fatty acid binding protein (FABP4/
aP2) (21) (Fig. 1F). In MonoMac-6 cells this represents the
induction of a single transcript (2 kb) (Fig. 1H and 2A).
Compounds with RAR selectivity (such as all-trans-retinoic
acid [ATRA] and AM580) and also one with RXR selectivity
(LG268) proved to be effective inducers, and we could detect
an increased induction upon treatment with the PPAR-spe-
cific Rosiglitazone in combination with the RXR-specific
LG268 (Fig. 1G, H, and I). In MonoMac-6 cells the retinoid
induction profile of CYP27 was very similar to that of macro-
phages (Fig. 1G). Among all of the PPAR activators tested,
interestingly, only oxidized LDL and its lipid component 9-hy-
droxyoctadecadienoic acid proved to be active on their own
in MonoMac-6 cells (Fig. 1I). Rosiglitazone induced CYP27
mRNA expression only in combination with the RXR-selective
LG268. This profile is very similar to the one reported by us on
the regulation of CD36 in another myeloid leukemia cell line
THP-1 (45). Significantly, neither PPAR- nor LXR-selective
ligands induced CYP27 in this cell type. PPAR agonist
showed an at least additive or synergistic response when com-
bined with LG268 (Fig. 1I).
In order to gain insight into the mechanism of induction, we
next wanted to test if this induction with PPAR agonists and
retinoids was acute or required prolonged exposure to the
compounds. As shown in Fig. 2A, Northern blot analysis re-
vealed that both retinoids (AM580 in this case) and the com-
bination of PPAR and RXR agonist induced an acute (after
2 to 6 h) induction of CYP27 transcription. These experiments
strongly suggested that RAR-RXR and PPAR-RXR hetero-
FIG. 2. Regulation of CYP27 is dose and time dependent. (A) Northern analysis was performed on RNA isolated from retinoid and PPAR
agonist-treated MonoMac-6 cells. (B) Real-time quantitative PCR analysis, showing a detailed time course of CYP27 induction, on RNA isolated
from MonoMac-6 cells treated as indicated. Cyclophilin D was used as a normalizer during quantitative PCR, unless indicated otherwise. (C)
ATRA was used to show the dose dependence of CYP27 induction in MonoMac-6 cells. (D and E) MonoMac-6 cells were cultured in the indicated
serum-containing medium for 2 days, and CYP27 (D) and transglutaminase (Tg) (E) mRNA levels (bars) were determined by quantitative
RT-PCR. The ATRA concentrations (D) in the various sera were measured by HPLC as described in Materials and Methods. CCSS, charcoal-
stripped medium; LpDS, lipoprotein-deficient medium. (F and G) MonoMac-6 cells cultured in fetal calf serum (FCS) were treated with the RAR
inverse agonist AGN193109, and CYP27 (F) and transglutaminase (G) mRNA levels were determined by quantitative PCR and compared to those
in AIMV. The means of at least three determinations 	 SD are shown. *, P 
 0.01; **, P 
 0.05 (compared to the respective control value).
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dimers can transcriptionally regulate the human CYP27 gene.
These observations were further substantiated by carrying out
time course experiments with RAR- and RXR-selective com-
pounds. As shown in Fig. 2B, both the RAR-selective AM580
and the RXR-selective LG268 induced CYP27 gene expres-
sion, while the combination of the two or the pan-agonist
9-cis-retinoic acid (9-cis-RA) proved to be more effective in-
ducers of gene expression. The efficacy of ATRA-induced ex-
pression was between those of the receptor-selective com-
pounds and the pan-agonists, indicating that perhaps some of
ATRA is converted into pan- or RXR-agonist compounds
during the course of the experiment.
In order to establish that the induction is dose dependent
and induced with doses biologically relevant for receptor acti-
vation, dose responses experiments were carried out. As shown
in Fig. 2C, ATRA induced CYP27 expression in a dose-depen-
dent manner in the range of 0.1 nM to 1 M. These experi-
ments established that CYP27 is acutely regulated by retinoids
in a dose- and time-dependent manner and that the doses
required for activation were in the same range as the Kds of the
compounds for the receptors. This raised the possibility that
endogenous retinoids might regulate CYP27 expression also.
We compared the expression levels of human CYP27 and a
known retinoid receptor target gene, that for tissue transglu-
taminase (14, 33), in MonoMac-6 cells cultured in four differ-
ent media (containing FBS, charcoal stripped, lipoprotein de-
ficient, or serum free), in which we determined endogenous
ATRA concentrations. We then plotted the mRNA levels of
CYP27 along with ATRA levels (Fig. 2D), which showed a
remarkable correlation. The more ATRA detectable in the
serum, the more transcripts were detectable. A similar profile
was obtained for tissue transglutaminase expression (Fig. 2E).
RAR levels did not change under the conditions used (data not
shown). Obviously, other differences between the different sera
may exist; therefore, in order to obtain further evidence on the
role of endogenous retinoids in the induction of CYP27, we
used a well-characterized RAR antagonist-inverse agonist
(AGN193109) to block activation through endogenous RARs.
Increasing amount of antagonist decreased the expression level
of CYP27 in serum (FBS)-containing medium by 50 to 60%
(Fig. 2F). Similarly, tissue transglutaminase expression was
also reduced (Fig. 2G). These two pieces of evidence did not
prove but strongly suggested that normal levels of endogenous
retinoids in serum are likely to contribute to the regulation of
CYP27 in myeloid cells and established human CYP27 as a
gene regulated by endogenous levels of retinoids.
RAR-RXR and PPAR-RXR heterodimers bind to and ac-
tivate the human CYP27 promoter. Our findings prompted us
to look at the previously defined promoter region of human
CYP27 (18). Using an 853-bp fragment, we carried out tran-
sient-transfection experiments examining whether receptor
heterodimers can activate this promoter. Cotransfection of
RAR and RXR and addition of 9-cis-RA induced a more than
a fivefold increase in promoter activity (Fig. 3A). Similarly,
cotransfection of PPAR and RXR in the presence of both
PPAR- and RXR-specific ligands increased transcriptional
activity (Fig. 3A and data not shown). These results indicated
that the 853-bp fragment contained all of the necessary infor-
mation to mediate both retinoid- and PPAR-dependent reg-
ulation. To define the response elements, we looked at various
deletion mutants of the 853-bp fragment (a 649-bp and a
217-bp fragment) and found that the detected induction was
approximately half of that for the 853-bp promoter fragment
(Fig. 3B) when a shorter fragment (649 bp) was used. An
additional deletion (217-bp fragment) led to retained core
promoter activity and to the complete loss of inducibility.
These experiments suggested that transcriptional regulation
takes place on the human CYP27 promoter by RAR-RXR and
PPAR-RXR heterodimers and raised the possibility that
more than one response element may be localized between bp
853 and 217. In silico analysis of the promoter identified
two regions with potential binding sites for RAR-RXR and
PPAR-RXR heterodimers. We termed these PPAR retin-
oid response elements (PRREs) A and B. The A element
contained an unusual arrangement of binding sites, with three
binding sites arranged in an overlapping DR1-DR5 configura-
tion (i.e., two direct repeats sharing a half site) (28, 34, 38, 46).
The B element looked simpler; it was a direct repeat separated
by one nucleotide (DR1).
Before embarking on a detailed promoter analysis, we
wanted to see whether the promoter was transcriptionally ac-
tive in myeloid cells and whether endogenous levels of recep-
tors were bound to the identified elements. We first carried out
chromatin immunoprecipitation experiments to assess the
acetylation status of histone 4 lysines. This would provide di-
rect evidence for promoter activation. Both 9-cis-RA and the
combination of LG268 and Rosiglitazone induced significant
acetylation of the promoter (data not shown). Next, we used
receptor-specific antibodies to immunoprecipitate chromatin
with RAR, RXR, and PPAR from ligand-treated Mono-
Mac6 cells. TaqMan probes were designed for PRRE-A and
PRRE-B, and the LXR PPAR response element as a positive
control, to quantitate reliably immunoprecipitated genomic
DNA. Both elements could be precipitated with the PPAR
antibody, while the RAR and RXR antibody readily immu-
noprecipitated the B element and to a much lesser degree
immunoprecipitated the A element. The LXR-PRRE was pre-
cipitated with the anti-RXR and anti-PPAR antibodies. Col-
lectively, the transfection and immunoprecipitation data estab-
lished that the identified region of the promoter was
transcriptionally active and that the B element could be im-
portant in the regulation of the gene, while the A element
might have an accessory role. Therefore, we continued with the
characterization of the B element.
Characterization of a response element mediating retinoid
and PPAR signaling. In order to test whether the identified
element could indeed bind receptor heterodimers in vitro, we
carried out electrophoretic mobility shift assays. Figure 4A
shows that the major element (hCYP27-PRRE-B) has a DR1
arrangement. Electrophoretic mobility shift assay analysis re-
vealed that this DR1 is able to mediate both PPAR-RXR and
RAR-RXR binding (Fig. 4A). Neither PPAR nor RXR alone
was able to bind to the labeled oligonucleotide; the two recep-
tors together show strong specific binding, which can be effec-
tively competed by either unlabeled self or a canonical DR1
oligonucleotide (Fig. 4A, left panel). The specificity of binding
was demonstrated by the use of antibodies against RXR and
PPAR, inducing supershifts or reduced binding, respectively
(Fig. 4A). A similar set of experiments was carried out with
RAR-RXR heterodimers. As shown in Fig. 4A (right panel)
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RXR-RAR heterodimers can bind to hCYP27-PRRE and this
binding can be competed by self and canonical DR5 elements.
RAR-RXR and PPAR-RXR can bind to the same element
utilizing a DR1. We have established a transfection-based as-
say for the determination of receptor binding independent of
transactivation in CV-1 cells, in which the transfection exper-
iments were carried out. By using VP16 fusion receptors (li-
gand mimic receptors) and transient transfection, we could
show a strong and robust binding of PRRE-B with VP-RXR
and with VP-RXR and PPAR (Fig. 4B). To prove that the
identified response element is a functional enhancer, enhancer
trap vectors were constructed by fusing two copies of the ele-
ment to a minimal TK promoter and a luciferase reporter
gene. Cotransfection analysis revealed that the identified ele-
ment conferred both RAR-RXR and PPAR-RXR hetero-
dimer responsiveness (Fig. 4C). Similar experiments carried
out with mutations in either of the two half-sites resulted in a
complete loss of induced transcription.
FIG. 3. The promoter of the human CYP27 gene is a direct target for complex regulation by RAR-RXR and PPAR-RXR heterodimers. (A
and B) CV-1 cells were cotransfected with hCYP27-853-pCAT, hCYP27-649-pCAT, hCYP27-217-pCAT, the indicated receptors, and -galac-
tosidase and treated with the receptor agonists 9-cis-RA (1 M), Rosiglitazone (1 M), both, or vehicle for 48 h. Cells were lysed, and the CAT
level and -galactosidase activity were assayed as described in Materials and Methods. CAT levels were normalized to -galactosidase activity. All
experiments were done in triplicates. The means of at least three determinations 	 SD are shown. (C) Chromatin immunoprecipitation was
performed with anti-RAR, anti-RXR, and anti-PPAR antibodies (ab), and the DNA content was determined with two quantitative PCR assays
specific for PRRE-B. DNA precipitated with anti-RXR and anti-PPAR antibodies was analyzed by a human LXR PPAR response element
(PPRE)-specific assay. The results are shown as percentages of input DNA. All measurements were done in triplicate. All chromatin results were
verified from independent chromatin preparations. *, P 
 0.01; **, P 
 0.05 (compared to the respective control [C] value).
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We have also analyzed the other in silico-found response
element (hCYP27-PRRE-A). There appears to be a discrep-
ancy between the in vitro binding and the apparent enhancer
activity of this element, because it shows strong in vitro binding
but only weak enhancer activity (data not shown). Therefore,
the role of the A element may be cell type specific or, more
likely, part of a more complex enhancer interaction in the
context of the full promoter. Based on these data, the B ele-
ment (hCYP27-PRRE-B) appeared to be critical in mediating
transcriptional activation, with a potentially minor contribu-
tion of a weak, accessory element (hCYP27-PRRE-A). Iden-
tification and analysis of this element provided evidence for
direct regulation and a potentially complex interplay between
retinoid and PPAR signaling on the human CYP27 promoter.
Retinoid- and PPAR-induced CYP27 expression results in
27-hydroxycholesterol formation and efflux. Having estab-
lished that the human CYP27 gene is transcriptionally regu-
lated by two nuclear receptor heterodimers (RAR-RXR and
PPAR-RXR), we next wanted to see what the biological
consequences of this regulation were. We carried out Western
blot analysis with MonoMac-6 cells treated with natural retin-
oids (ATRA or 9-cis-RA). Protein expression was increased, as
demonstrated by the appearance of the expected single 59-kDa
band (Fig. 5A, inset). In order to establish that the protein is
functional, we carried out mass spectrometric determination of
the metabolic products of CYP27 from cell pellets and medium
supernatants. The determined compounds were 27-hydroxy-
cholesterol and 3-hydroxy-5-cholestenoic acid. MonoMac-6
cells were treated with the indicated nuclear receptor ligand
and simultaneously loaded with cholesterol. After 2 days, 27-
hydroxycholesterol and 3-hydroxy-5-cholestenoic acid levels
in the supernatant and cell pellet were determined. As shown
in Fig. 5A and B, treatment with the naturally occurring reti-
noids ATRA and 9-cis-RA as well as a synthetic ligand for
RAR (AM580) or RXR (LG268) induced 27-hydroxycholes-
terol formation and release to the medium (data not shown).
Combinations of RAR and RXR ligands, i.e., PPAR and RXR
or PPAR and RXR ligands, also induced this effect. Neither
Rosiglitazone nor a synthetic PPAR ligand (GW501516) was
able to induce 27-hydroxycholesterol formation on its own.
Ligands for LXR alone or in combination with RXR ligands
failed to induce it also. In molar terms, the supernatant con-
tained 20 to 50 nM 27-hydroxycholesterol, while the highest
intracellular levels deduced from the pellets were approxi-
mately 12 to 20 M. It is unsettled whether high levels of 27-
hydroxycholesterol are able to activate LXR-RXR hetero-
dimers to sufficiently high levels.
The fact that retinoids were able to induce the enzyme’s
expression and also to synergize with the enzyme’s product
offered a testable hypothesis. It is possible that under some
conditions both retinoids and 27-hydroxycholesterol are re-
quired for full activation of LXR-RXR heterodimers. We
tested this hypothesis by looking at LXR-dependent gene ex-
pression induced by retinoids and 27-hydroxycholesterol. As
shown in Fig. 5C, LG268 and 9-cis-RA synergize with 27-
hydroxycholesterol to induce gene expression to a very signif-
icant degree. Note that 27-hydroxycholesterol at 10 M was
able to induce a 14-fold induction, while if it was combined
with 9-cis-RA, the induction was further induced by an addi-
tional 19-fold, resulting in a nearly 300-fold induction alto-
FIG. 4. Identification of RXR-RAR and RXR-PPAR binding
sites in the human CYP27 promoter. (A) Electrophoretic mobility shift
analysis for hCYP27-PRRE-B was performed by using in vitro-trans-
lated receptors of mPPAR and hRXR (left panel) and hRAR and
hRXR (right panel) and 32P-labeled oligonucleotides in the absence
or presence of the indicated ligands (Rosiglitazone [1 M] or 9-cis-RA
[1 M]) as described in Materials and Methods. For competition ex-
periments, cold hCYP27-PRRE-B (self [S]), consensus DR1, or DR5
was used at 10 and 20 concentrations. For supershift experiments,
the receptors were preincubated with the indicated antibodies prior to
the binding reaction. (B) The response element was analyzed in a
cell-based binding assay. The indicated VP fusion nuclear receptors
were cotransfected with the response element containing a luciferase
reporter plasmid, and the normalized reporter activity 	 SD are
shown. (C) Two copies of hCYP27-PRRE-B and half-site mutants
were cloned upstream from the TK-Luc reporter. They were cotrans-
fected into CV-1 cells with the indicated receptors and -galactosidase
and treated with the indicated ligands: AM580 (100 nM), Rosiglita-
zone (1 M), LG268 (100 nM), or vehicle. Luciferase activity was
normalized to -galactosidase activity. *, P 
 0.01 compared to the
respective control value.
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FIG. 5. Induction of CYP27 is accompanied by increased enzyme activity that leads to production of 27-hydroxycholesterol. (A) MonoMac-6
cells were treated with water-soluble cholesterol (100 g/ml) and the indicated ligands for 2 days in RPMI supplemented with insulin-transferrin-
sodium selenite medium supplement. 27-Hydroxyxholesterol and 3-hydroxy-5-cholestenoic acid contents in the cell pellet were determined and
normalized to cell number as described in Materials and Methods. The inset shows Western blot analysis of CYP27 protein levels in MonoMac-6
cells treated with ATRA (1 M), 9-cis-RA (1 M), or vehicle (for details, see Materials and Methods). (B) As for panel A, MonoMac-6 cells were
cholesterol loaded and treated with ligands or vehicle as indicated, and 27-hydroxycholesterol was determined. (C) MonoMac-6 cells were treated
with increasing amounts of 27-hydroxycholesterol, and a dose-response curve was determined. To analyze synergy, cells were treated with ATRA
(1 M), 9-cis-RA (1 M), AM580 (100 nM), or LG268 (100 nM) and 27-hydroxycholesterol simultaneously. Transcript levels of ABCA1 were
measured by real-time quantitative RT PCR and normalized to cyclophilin levels. The results are shown on a logarithmic scale. (D) CV-1 cells were
cotransfected with Gal-hLXR-LBD, hRXR-LDB, pMH100-TK-Luc, and -galactosidase plasmids and treated with LXR activators 25-
hydroxycholesterol, 27-hydroxycholesterol, and 24(S)25-epoxycholesterol at the indicated concentrations in the absence or presence of 9-cis-RA
(1 M). Luciferase activity was normalized to -galactosidase activity, and EC50s values were calculated from the dose-response curves (inset). *,
P 
 0.01 compared to the respective control value.
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gether. These data suggest that retinoids via the induction of
a partial agonist of LXR gain competence to induce robust
LXR-dependent transcription. This notion was further sub-
stantiated by determining the 50% effective concentrations
(EC50s) for 27-hydroxycholesterol alone and in combination
with 9-cis-RA in better-defined transient-transfection experi-
ments. Figure 5D shows that 27-hydroxycholesterol is able to
induce LXR-dependent gene expression with an EC50 of 2 
107 M and that addition of 9-cis-RA increased the efficacy of
the response. EC50s of other oxysterols were also determined
(Fig. 5D, inset) for reference in the same assay. These fall in
the same range as that of 27-hydroxycholesterol.
Retinoids induce LXR-mediated gene expression, which in-
volves activation of CYP27. After having established that reti-
noids and PPAR ligands induce CYP27 expression and that
this leads to the formation of 27-hydroxycholesterol in biolog-
ically relevant quantities, we sought to understand the biolog-
ical consequence of this induction. One of the key biological
consequences of the pathway described, one may predict, is the
induction of LXR responses. To address this issue, we treated
human monocyte-derived macrophages with various RAR,
RXR, and PPAR ligands and determined the expression lev-
els of key LXR target genes, ABCA1 and ABCG1. As shown
in Fig. 6A and B, retinoids and LXR ligand induced ABCA1
and ABCG1 to various degrees. The induction of ABCA1 and
ABCG1 by RXR or pan-retinoid agonist ligands is not unex-
pected, since they are believed to regulate LXR-RXR hetero-
dimers from the RXR side, but the RAR-selective ligand
AM580 could also induce ABCA1 and ABCG1 (Fig. 6A and
B). Combinations of RAR and RXR ligands were slightly
better than the RXR ligand alone. Our findings therefore
suggest that retinoid induction of LXR target genes could
involve activation of CYP27 and production of 27-hydroxycho-
lesterol. To obtain genetic evidence for the role of CYP27 in
the described regulatory network and its biological relevance,
we used primary cell lines derived from patients with CYP27
deficiency (CTX). We could demonstrate that retinoids in-
duced CYP27 expression not only in myeloid cells but also in
fibroblasts (Fig. 6C) and that retinoid-induced ABCA1 expres-
sion is strongly attenuated in the absence of CYP27 (in CTX
fibroblasts) (Fig. 6D).
Evidence for retinoid- and PPAR-regulated gene expres-
sion in human atherosclerotic lesions. In order to obtain evi-
dence for the physiological relevance and disease relatedness
of the described pathway in atherosclerosis, a disease linked to
macrophage cholesterol metabolism, we analyzed the gene ex-
pression profile of human macrophage-rich atherosclerotic le-
sions. mRNA levels of LXR, PPAR, and their relevant tar-
get genes ABCA1, CD36, and CYP27 were determined from
lesions and lesion-free intima and vessel wall tissue, along with
transcript levels of enzymes responsible for the production of
ATRA retinaldehyde dehydrogenase (RALDH2) and a marker
gene for retinoid action, CD38. Lesions were defined as ab-
normal fatty tissue on the luminar side of the internal elastic
membrane of arteries. As shown in Fig. 7, in human lesions
remarkable increases of PPAR (Fig. 7B), LXR (Fig. 7D),
and their target genes ABCA1 (Fig. 7G), CD36 (Fig. 7E), and
CYP27 (Fig. 7C) were detected, compared to those in normal
vessel wall, along with high expression of RALDH2 and CD38
(Fig. 7F and data not shown). These data suggest that lesion
tissue (mostly macrophages) has an expression profile similar
to that of in vitro differentiated macrophages showing retin-
oid-, PPAR-, and LXR-regulated transcription, including in-
creased CYP27 expression. These data collectively provide a
FIG. 6. Retinoid-induced CYP27 promotes an LXR response. Primary human monocytes were isolated and treated with the indicated reti-
noids. Total RNA was isolated, and ABCA1 (A) and ABCG1 (B) mRNA levels were determined by real-time quantitative RT-PCR. (C and D)
Primary human fibroblasts isolated from healthy adults and patients with CTX (CYP27/) were treated with the indicated ligands for 2 days. Total
RNA was isolated, and CYP27 (C) and ABCA1 (D) mRNA levels were determined by real-time quantitative RT-PCR. *, P 
 0.01; **, P 
 0.05
(compared to the respective control value).
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very strong link and correlation between retinoid, PPAR, and
LXR signaling in the context of human macrophage-rich ath-
erosclerotic lesions and also establish CYP27 as a potentially
key mediator of this interrelated signaling network.
DISCUSSION
We have identified the gene for a p450 enzyme, CYP27, as
a gene commonly induced during monocyte-macrophage tran-
sition and as a PPAR-RXR- and RAR-RXR-regulated gene
FIG. 7. Elements of the retinoid-PPAR-CYP27-LXR pathway are present in human macrophage-rich atherosclerotic lesions. (A) A human
femoral artery containing a macrophage-rich fatty lesion was dissected, and total RNA was extracted from the indicated parts. 1, normal intima; 2,
normal media and adventitia; 3, intima of atherosclerotic lesion; 4, media and adventitia of atherosclerotic lesion. (B to G) Transcript levels of the
indicated genes were measured by real-time PCR and normalized to cyclophilin levels. Three similar lesions from various individuals were analyzed with
essentially the same results. Results from a representative experiment are presented. *, P
 0.01 compared to the respective control value. (H) Integration
of retinoid, PPAR, and LXR signaling via CYP27, leading to enhanced LXR-dependent and -independent cholesterol efflux. TZD, thiazolidinedione.
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in myeloid cells. Promoter analysis revealed complex regula-
tion by retinoid receptors and PPARs via a response element
on the promoter of human CYP27, further underscoring the
interrelatedness of these pathways. These findings tie retinoid,
PPAR, and LXR signaling into one regulatory network requir-
ing natural ligands: retinoids and modified fatty acids or pro-
stanoids to activate an entire metabolic pathway and leading to
coordinate regulation of lipid and cholesterol uptake, metab-
olism, and efflux (Fig. 7H). Furthermore, we provided evidence
that all components of the described pathways exist in human
atherosclerotic lesions.
Applying synthetic ligands to biological systems allows the
identification of pathways attributable to the receptors. This
proved to be a very fruitful approach to identify biological
processes activated by the receptors, but it also overrides the
need for the identification of natural ligands and, more impor-
tantly, sources and regulation of natural ligand production.
This approach may also represent superphysiological and ec-
topic activation of receptors. This is a particular concern in
cases of the metabolite receptors (PPARs, LXRs, farnesoid X
receptor, and pregnane X receptor), for which only low-affinity
natural ligands have been identified so far, because activation
with low-affinity (partial agonist) ligands may lead to a biolog-
ical outcome different from that for activation with a synthetic
full agonist. Therefore, the processes and enzymes leading to
endogenous ligand production and their regulation should be
also considered when assigning biological functions to recep-
tors. This line of argument led us to search for mechanisms
linking PPAR-RXR and LXR-RXR signaling pathways. In
the case of LXR, several low-affinity oxysterols [22(R)-cho-
lesterol, 20(S)-cholesterol, and 24-, 25- and 27-hydoxycholes-
terol] have been identified as endogenous ligands (17, 24, 25,
31, 36), but none of them has an affinity higher than 10 M. It
is important to note that among these oxysterols 27-hydroxy-
cholesterol is present at the highest concentration in the cir-
culation (15), suggesting an in vivo relevance in activation of
LXR. We identified CYP27 as a nuclear receptor-regulated
enzyme that is capable of producing endogenous ligands for
LXR. Moreover, pan-agonists or RXR-activating retinoids can
contribute to receptor activation, resulting in a robust syner-
gistic response between retinoids and oxysterols. The linkage
of regulated enzyme expression and heterodimer activation
suggests that partial agonists such as 27-hydroxycholesterol can
contribute to full activation in the presence of the appropriate
retinoid. This adds an additional layer of control to the recep-
tor’s activity by the regulation of the production of two endog-
enous lipid molecules.
CYP27 is an attractive target for regulated transcription
because its product is an alternative bile acid synthesis precur-
sor in the liver. Identification of a complex PPAR-RAR regu-
lation and the fact that retinoids present in the serum regulate
the basal expression level of the enzyme in myeloid cells are
significant novel aspects of the enzyme’s regulation. The prod-
uct generated, 27-hydroxycholesterol, is a polar compound ca-
pable of transversing membranes and therefore provides an
alternative cholesterol efflux mechanism (3, 5, 16). The fact
that 27-hydroxycholesterol is an endogenous ligand of LXR
has been noted previously (17, 25). It was even suggested that
27-hydroxycholesterol is a partial agonist of LXR-RXR het-
erodimers (17). Our results are in agreement with this assess-
ment, but they go further and show that ligand production can
be regulated and that, in combination with retinoids, 27-hy-
droxycholesterol becomes a full agonist on LXR-regulated tar-
get genes. The fact that retinoids (RAR- and RXR-selective
compounds) and combinations of PPAR- and RXR-selective
compounds were able to induce CYP27 expression suggested
that there is a cross talk between retinoid and PPAR signaling.
This became apparent when the promoter analysis revealed
the two enhancers mediating the effects. Further studies iden-
tified PRRE-B as the major element and regulator of human
CYP27 gene transcription, while PRRE-A might serve as an
accessory site required for full activation. Further studies are
needed to define the relationship between the two elements
and the two heterodimers (RAR-RXR and PPAR-RXR)
binding to them. The chromatin immunoprecipitation assays
suggest two possibilities: one is that both heterodimers could
bind in one complex, and the other is that there is heteroge-
neity between the cells and that some bind one heterodimer
and some bind the other heterodimer. It may also be possible
that the two elements and two heterodimers are part of a
larger complex (i.e., an enhancesome). Traditional promoter-
enhancer analysis is not sufficient to dissect such complex re-
lationships. Another interesting aspect of the cross talk be-
tween retinoid and PPAR signaling is the fact that PPAR
ligands are active in regulating CYP27 expression only if rexi-
noids are present in some of the cell lines used. We termed this
the retinoid-enabled PPAR response. This phenomenon can
be observed in the monocytic leukemia cell line MonoMac-6,
and a similar observation was also made during the transient-
transfection-based analysis of the promoter. This is in line with
our initial observations on oxidized LDL uptake regulated by
PPAR-RXR heterodimers (35). At this point it is not clear
whether the identified elements are solely responsible for this
effect or whether other factors contribute to it.
Regulated expression of CYP27 is also of interest because
CYP27 has a key metabolic function, converting cholesterol
into a more polar compound, 27-hydroxycholesterol. Conse-
quently, it has two major effects on cholesterol efflux. It in-
duces ABC transporter expression and subsequent high-den-
sity lipoprotein-dependent efflux via the activation of LXR-
RXR. 27-Hydroxycholesterol also represents an alternative
cholesterol efflux pathway from macrophages that is indepen-
dent of known transporters, including ABCs and high-density
lipoprotein, and allows converted cholesterol to leave the cells
and be cleared by the liver as bile acids. It is estimated that
under steady-state conditions it may represent as much as 10 to
20% of total cholesterol efflux, as was shown by Babiker et al.
(2). Our data suggest that this efflux in macrophages may be
regulated by retinoid- and PPAR-mediated induction of
CYP27. It is also apparent that besides cholesterol efflux,
LXR-RXR heterodimers are capable of inducing multiple
other pathways involved in lipid metabolism, such as SREBP1c
induction (39, 49) or the induction of phospholipid transport
protein (29), and that they have a more global effect on mac-
rophage lipid homeostasis. As far as the physiological rele-
vance of the pathway is concerned, due to the species speci-
ficity of this regulation (it exists in human but not in mouse)
and the lack of suitable mouse models, we had to rely on
approaches involving gathering of data from CTX (CYP27/)
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human fibroblasts and atherosclerotic lesions of humans. The
evidence from these approaches clearly demonstrates that
CYP27 is required, at least in part, for retinoid and PPAR
ligand-induced LXR-mediated gene expression and potentially
for cholesterol efflux. The striking similarity between gene ex-
pression patterns, including retinoid-, PPAR-, and LXR-reg-
ulated gene expression as well as high levels of CYP27, in in
vitro-differentiated macrophages and in tissue samples of mac-
rophage-rich atherosclerotic lesions also underscores that this
regulatory network is likely to have physiological and disease
relevance. A recent study by Costet et al. (12) suggested that
ABCA1 and cholesterol efflux can be regulated directly by
retinoids via an RAR-mediated pathway. Our data presented
here show that RAR activation has a broader effect on hu-
man macrophage cholesterol metabolism, as those authors
suggested. We suggest that retinoid-regulated CYP27 is likely
to act as a modulator of a robust LXR response. In our view,
the identified pathway also represents a potential new target
for the regulation of macrophage cholesterol efflux and for the
management of diseases with increased foam cell formation
and cholesterol overload. It also suggests that retinoids may
have a more profound effect on lipid metabolism than previ-
ously suspected. This notion is further underscored by the
observation that RXR agonists have a atheroprotective effects
in ApoE/ mice (11). Clearly, more work needs to be done
before regulation of CYP27 can be considered a valid target
for pharmacological intervention in these conditions.
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